(IPSS) in prostate cancer patients who received image-guided volumetric modulated arc therapy (IG-VMAT).

Materials and Methods: From August 2008 to November 2011, 190 consecutive prostate cancer patients were treated with IG-VMAT to a dose of 76 Gy with daily correction of the target position based on cone-beam CT imaging. The IPSS and Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 toxicity were prospectively scored before VMAT, at the end of VMAT, 1, 3, 6, 12, 18, 24 and 36 months after VMAT. IPSS resolution was defined as a return to within 1 point of the score at baseline. Clinical, treatment-related parameters were evaluated including patient age, alpha-blocker use, androgen deprivation therapy (ADT) use, body mass index, diabetes, hypertension, smoking and drinking habits, and prostate volume. Dosimetric quality indicators were also examined.

Results: The median follow-up was 24.2 months (range, 11.3-47.6). 134 (70.5%) patients took ADT medications. At last follow-up, 67 (35.3%) patients took alpha-blocker medications. The 2-year actuarial rate of grade 2 or greater genitourinary toxicity was 2.6%. The median (inter-quartile range) IPSS before VMAT, at the end of VMAT, 1, 3, 6 months after VMAT and at last follow-up were 3(1-7), 9(5-12), 6(2-9), 3(1-8), and 4(1-7), respectively. The IPSS returned to baseline at a median of 3.0 months. The IPSS of 49 patients (25.8%) didn’t exceed baseline more than 2 months after VMAT. IPSS resolution was substantially, within 3 months, in 123 patients (64.7%). Side effects of drinking during radiotherapy may be useful for further improvement.

PO-0370  
Stereoablatif aortic radiotherapy (SARB) of primary and metastatic renal lesions for patients with single kidney.

T. Chebotareva1, N. Spizhenko1, V. Buryk1, Y. Lesenko1, D. Mechev2, O. Potlih1, O. Sharaevskiy1, A. Leonovich1

1Cyber Clinic of Spizhenko, CyberKnife Radiosurgery, Kapitanivan – Kyiv, Ukraine

Purpose/Objective: Most researchers consider kidney cancer radioresistant and in light of this what seems to be the 'common knowledge' use of radiation therapy to treat those lesions is not effective. An analysis of traditional approach indicate the possibility of changing this dogma, aiming to achieve positive results in the implementation of radiosurgical abilities to deliver ablative radiation doses by means of radiosurgical system CyberKnife.

Materials and Methods: Fifty patients with medically inoperable renal cell cancer (RCC), (from October 2010 to December 2012) were treated with robotic SWBT CyberKnife modalities. Eighteen (18) of them were diagnosed with single kidney (RCC). All 18 patients had metastases from malignant kidney to contralateral kidney and three of them had metastases spread to brain, lung, and pancreas. Dose/fractionation schedules varied between 10 to 13 Gy per fraction and 3 to 4 sessions on kidney and 15 to 20 Gy, 1 to 3 sessions on other metastases depending on target location, and size. Tumor volume varied from 5 to 180 cc. Follow-up times for patients who remained alive were 6 to 25 months and for those who died (2patients) were 14 to17 months.

Results: All eighteen patients were carefully followed by multidisciplinary team, contrasted CT scans, renal scintigraphy, and blood work was analyzed. Local controls defined as radiologically stable disease or partial/complete response was obtained in all eighteen patients with single kidney. A partial response as defined as a greater than 50% reductions tumor volume was noted in 8 cases. No patient was reported with grade 2 to 4 toxicity. Parameters of the dynamic renal scintigraphy not affected by the radiosurgery. Side effects were mild, grade 1 in 8 cases. No patient was reported with grade 2 to 4 toxicity. No complications of the fiducial placement reported.

Conclusions: The results show positive effect of treatment. These can be evaluated as an alternative to surgery and provide local control while maintaining the function of a single kidney. Stereotactic body radiation therapy (SBRT) also known as stereotactic ablative radiotherapy (SARB), is emerging as one of the new treatment options for renal cell cancer (RCC) mainly in medically inoperable patients especially reducing surgical risks in patients with single remaining kidney.

POSTER: CLINICAL TRACK: GYNAECOLOGICAL TUMOURS

PO-0732  
Clinical trial of carbon ion radiotherapy for gynecological melanoma.

K. Karasawa1, M. Wakatsuki1, T. Kamada1

1National Institute of Radiological Sciences, Research Center Hospital for Charged Particle Therapy, Chiba-city, Japan

Purpose/Objective: To evaluate a toxicity and efficacy of carbon ion radiotherapy for gynecological melanoma, we conducted a Phase I/II clinical trial.

Materials and Methods: The eligibiltycriterion for enrollment in this study were (1) histologically proven malignantmelanoma, (2) a locally measurable tumor in gynecological region, (3) at least a 5 mm gap between the tumor and radiosensitive organs, including bowel and bladder, and (4) a expected prognosis of more than 6 months. Tumors were classified by TNM classification for malignant melanoma. In principle, tumors with PTV margins were irradiated 3.6 GyE per fraction up to the total dose of 57.6 GyE in 16 fractions, 4 times a week. Acute toxicities were assessed according to NCI-CTCAE ver.4.0 within 3 months after the treatment. Treatment response was assessed at 3 month after treatment completion. Late toxicities were assessed according to RTOG/EORTC scoring system. Safety and feasibility analysis of local control and survival were calculated using the Kaplan-Meier method.

Results: A series of 23 gynecological melanoma patients were treated with carbon ion radiotherapy between November 2004 and October 2012. The age ranged from 51 to 80 with a median of 71. The tumor